NASDAQ$BCRX
BioCryst Pharmaceuticals Inc · Q1 2020 earnings
Q1 2020 earnings · · Investor relations
Briefing
BioCryst's financial performance for Q1 2020 was detailed, highlighting revenue and expenses, along with program updates and key milestones.
BioCryst reported a decrease in total revenues to $4.8 million compared to $5.9 million in the first quarter of 2019. The net loss for the quarter was $37.6 million, or $0.24 per share, compared to a net loss of $31.1 million, or $0.28 per share, for the first quarter of 2019. The company's cash, cash equivalents, and investments totaled $114.6 million at the end of March 2020.
- Berotralstat approval and launch timelines in the U.S., Japan, and EU remain on track.
- Early clinical data supports BCX9930 as an oral monotherapy for complement-mediated diseases.
- Patient dosing is underway in the galidesivir trial for COVID-19 patients in Brazil.
- Company prepares to launch berotralstat in multiple territories to bring their oral, once-daily prophylactic medicine to HAE patients.
Headline financials
Revenue & EPS history
BioCryst · Revenue · Quarterly
$4.82M
Forward guidance
BioCryst expects full year 2020 net operating cash use to be in the range of $125 to $150 million, and its operating expenses to be in the range of $135 to $160 million.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2020
-0.3%
Avg return
Earnings day
+3.1%
Avg return
5 days after
+5.6%
Avg return
30 days after
41%
26 / 64 earnings
Positive
+26.0%
Q2 2022
Best reaction
-38.0%
Q3 2012
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -2.2% | -5.0% | -7.0% | |
| Q4 2025 | +4.8% | +15.1% | +23.6% | |
| Q3 2025 | -5.4% | -3.1% | +7.2% | |
| Q1 2025 | +23.7% | +11.6% | +23.6% | |
| Q4 2024 | -10.0% | -6.5% | -15.3% | |
| Q3 2024 | -16.3% | -7.7% | -13.0% | |
| Q2 2024 | +12.1% | +8.7% | +17.9% | |
| Q1 2024 | +18.2% | +19.6% | +52.6% | |
| Q4 2023 | +2.8% | -1.6% | -9.8% | |
| Q3 2023 | +5.4% | +5.9% | +7.3% | |
| Q2 2023 | +9.4% | +1.0% | +4.7% | |
| Q1 2023 | +14.9% | +15.2% | +13.3% | |
| Q4 2022 | -4.2% | -10.8% | -20.4% | |
| Q3 2022 | -10.0% | -6.8% | -2.9% | |
| Q2 2022 | +26.0% | +29.6% | +26.2% | |
| Q1 2022 | -10.7% | -15.5% | +2.7% | |
| Q4 2021 | -6.0% | -6.4% | -9.9% | |
| Q3 2021 | -23.3% | -19.3% | -24.4% | |
| Q2 2021 | +8.3% | -6.5% | -3.7% | |
| Q1 2021 | +22.8% | +13.7% | +52.5% | |
| Q4 2020 | -8.7% | -0.6% | -12.4% | |
| Q3 2020 | -4.4% | -4.4% | +42.9% | |
| Q2 2020 | -5.7% | -5.9% | -13.1% | |
| Q1 2020 | -0.8% | +40.3% | +5.6% | |
| Q4 2019 | +17.1% | -19.9% | -44.4% | |
| Q3 2019 | +1.5% | -5.9% | +31.5% | |
| Q2 2019 | -2.1% | -0.4% | +10.6% | |
| Q1 2019 | +1.7% | -1.0% | -54.0% | |
| Q4 2018 | -3.0% | -7.5% | +0.2% | |
| Q3 2018 | +0.8% | -2.9% | +12.9% | |
| Q2 2018 | +9.2% | +24.8% | +31.1% | |
| Q1 2018 | -4.1% | -1.1% | +10.4% | |
| Q4 2017 | -1.6% | -0.4% | -5.5% | |
| Q3 2017 | -3.1% | -0.6% | -5.8% | |
| Q2 2017 | -12.0% | -11.2% | -2.7% | |
| Q1 2017 | -12.4% | -13.4% | -14.7% | |
| Q4 2016 | +13.7% | +39.9% | +54.6% | |
| Q3 2016 | +19.4% | +36.6% | +40.9% | |
| Q2 2016 | +2.7% | +22.8% | +4.2% | |
| Q1 2016 | -5.3% | — | — | |
| Q4 2015 | -12.0% | — | — | |
| Q3 2015 | -7.6% | — | — | |
| Q2 2015 | -14.1% | — | — | |
| Q1 2015 | +9.2% | — | — | |
| Q4 2014 | -0.1% | — | — | |
| Q3 2014 | +8.1% | — | — | |
| Q2 2014 | -1.4% | — | — | |
| Q1 2014 | +4.6% | — | — | |
| Q4 2013 | -6.0% | — | — | |
| Q3 2013 | +13.2% | — | — | |
| Q2 2013 | -9.1% | — | — | |
| Q1 2013 | -2.7% | — | — | |
| Q4 2012 | -1.6% | — | — | |
| Q3 2012 | -38.0% | — | — | |
| Q2 2012 | -1.2% | — | — | |
| Q1 2012 | -0.5% | — | — | |
| Q4 2011 | +0.2% | — | — | |
| Q3 2011 | -2.0% | — | — | |
| Q2 2011 | -18.0% | — | — | |
| Q1 2011 | +3.0% | — | — | |
| Q4 2010 | -2.6% | — | — | |
| Q3 2010 | -3.2% | — | — | |
| Q2 2010 | -5.1% | — | — | |
| Q1 2010 | +2.1% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro